Nirsevimab to reduce infant morbidity from respiratory syncytial virus.
作者信息
Abu-Raya Bahaa, Langley Joanne M, Lavoie Pascal
机构信息
Canadian Center for Vaccinology (Abu-Raya, Langley), Dalhousie University, IWK Health Centre and the Nova Scotia Health Authority; Departments of Pediatrics (Abu-Raya, Langley), of Microbiology and Immunology (Abu-Raya), and of Community Health and Epidemiology (Langley), Dalhousie University, Halifax, NS; Department of Pediatrics (Lavoie), University of British Columbia, Vancouver, BC.
出版信息
CMAJ. 2024 Sep 30;196(32):E1114-E1117. doi: 10.1503/cmaj.240780.
Abstract
摘要
相似文献
1
Nirsevimab to reduce infant morbidity from respiratory syncytial virus.尼塞韦单抗可降低呼吸道合胞病毒引起的婴儿发病率。
CMAJ. 2024 Sep 30;196(32):E1114-E1117. doi: 10.1503/cmaj.240780.
2
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.尼塞维单抗用于患有心脏或肺部疾病或早产的婴儿预防呼吸道合胞病毒感染的安全性
N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186.
3
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).从医学上脆弱的儿童中分离出的呼吸道合胞病毒株的分子和表型特征：尼司特韦单抗（MEDLEY）的 2/3 期随机、双盲、帕利珠单抗对照试验的探索性分析。
Vaccine. 2024 Oct 24;42(24):126276. doi: 10.1016/j.vaccine.2024.126276. Epub 2024 Sep 5.
4
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.尼氏病毒单抗免疫接种预防婴儿和儿童呼吸道合胞病毒相关下呼吸道感染（24 月龄以下）
Nurs Womens Health. 2024 Feb;28(1):75-79. doi: 10.1016/j.nwh.2023.11.002. Epub 2023 Dec 6.
5
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.帕利珠单抗用于预防早产儿呼吸道合胞病毒感染。
Klin Padiatr. 2017 Sep;229(5):259-260. doi: 10.1055/s-0043-116334. Epub 2017 Sep 19.
6
RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection.呼吸道合胞病毒前体融合蛋白疫苗（Abrysvo）和奈赛韦单抗-阿利泼素（Beyfortus）用于预防呼吸道合胞病毒感染
Am Fam Physician. 2024 Jun;109(6):578-579.
7
Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.帕利珠单抗预防高危婴儿呼吸道合胞病毒感染：一则警示
J Paediatr Child Health. 2003 Nov;39(8):637. doi: 10.1046/j.1440-1754.2003.00253.x.
8
Nirsevimab: Reducing RSV Infections in Infants.尼塞韦单抗：减少婴儿呼吸道合胞病毒感染
Ir Med J. 2024 Jun 27;117(6):970.
9
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing.Nirsevimab 和帕利珠单抗给药后的 RSV 中和抗体。
Pediatrics. 2024 Nov 1;154(5). doi: 10.1542/peds.2024-067174.
10
[Palivizumab prophylaxis against respiratory syncytial virus. Should its indications be reviewed?].[帕利珠单抗预防呼吸道合胞病毒。其适应证是否应重新评估？]
An Pediatr (Barc). 2004 Jan;60(1):87-8. doi: 10.1016/s1695-4033(04)78222-3.
引用本文的文献
1
Characterisation of the respiratory syncytial virus seasonality and its environmental factors in the Americas-a multi-country observational study using routine surveillance networks.美洲地区呼吸道合胞病毒季节性特征及其环境因素——一项利用常规监测网络的多国观察性研究
Lancet Reg Health Am. 2025 Jul 7;48:101166. doi: 10.1016/j.lana.2025.101166. eCollection 2025 Aug.
2
Respiratory syncytial virus vaccination in pregnancy.孕期呼吸道合胞病毒疫苗接种
CMAJ. 2024 Sep 30;196(32):E1118-E1119. doi: 10.1503/cmaj.240773.
本文引用的文献
1
Respiratory syncytial virus vaccination in pregnancy.孕期呼吸道合胞病毒疫苗接种
CMAJ. 2024 Sep 30;196(32):E1118-E1119. doi: 10.1503/cmaj.240773.
2
Population Attributable Risk of Wheeze in 2-<6-Year-old Children, Following a Respiratory Syncytial Virus Lower Respiratory Tract Infection in The First 2 Years of Life.2至6岁儿童喘息的人群归因风险，源于生命最初2年内呼吸道合胞病毒下呼吸道感染。
Pediatr Infect Dis J. 2025 May 1;44(5):379-386. doi: 10.1097/INF.0000000000004447. Epub 2024 Jul 1.
3
Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials.来自所有关键随机临床试验的关于Nirsevimab在婴幼儿中的安全性数据综合总结。
Pathogens. 2024 Jun 13;13(6):503. doi: 10.3390/pathogens13060503.
4
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain.2023 年第 40 周至 2024 年第 8 周期间，西班牙 1 岁以下儿童因呼吸道合胞病毒感染需住院治疗的预估影响：尼赛珠单抗
Influenza Other Respir Viruses. 2024 May;18(5):e13294. doi: 10.1111/irv.13294.
5
Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people.呼吸道合胞病毒在婴幼儿、孕妇及人群中的疾病负担
Can Commun Dis Rep. 2024 Jan 1;50(1-2):1-15. doi: 10.14745/ccdr.v50i12a01.
6
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.尼赛珠单抗预防婴儿呼吸道合胞病毒住院治疗。
N Engl J Med. 2023 Dec 28;389(26):2425-2435. doi: 10.1056/NEJMoa2309189.
7
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 Pandemic.儿科呼吸道合胞病毒相关住院治疗在 COVID-19 大流行之前和期间。
JAMA Netw Open. 2023 Oct 2;6(10):e2336863. doi: 10.1001/jamanetworkopen.2023.36863.
8
Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational study.加拿大不列颠哥伦比亚省2019冠状病毒病大流行之前及期间呼吸道合胞病毒的流行病学与临床严重程度：一项回顾性观察研究
Lancet Reg Health Am. 2023 Aug 30;25:100582. doi: 10.1016/j.lana.2023.100582. eCollection 2023 Sep.
9
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.在患有心脏或肺部疾病的儿童中，在 RSV 季节 2 之前重新给予 Nirsevimab 的安全性。
J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):477-480. doi: 10.1093/jpids/piad052.
10
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.尼塞利珠单抗预防早产儿和足月儿呼吸道合胞病毒下呼吸道感染的疗效，以及对伴有先天性心脏病和慢性肺部疾病的婴儿的药代动力学外推：一项随机对照试验的汇总分析。
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
Zotero 插件